Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock

European Journal of Pharmacology

Volumn 640, Issue 1-3, 2010, Pages 172-177

  Łukawski, Krzysztof ^a   Janowska, Agnieszka ^a   Jakubus, Tomasz ^a   Tochman Gawda, Anna ^a   Czuczwar, Stanisław J ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antiepileptic drugs; Losartan; Maximal electroshock; Pharmacodynamic interaction; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CARBAMAZEPINE; LOSARTAN; LUMINALUM; PHENOBARBITAL; PHENYTOIN; TELMISARTAN; UNCLASSIFIED DRUG; VALPROIC ACID; XARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CONVULSION; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG POTENTIATION; ELECTRIC SHOCK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; ANIMAL; ANIMAL BEHAVIOR; BLOOD; BRAIN; DISEASE MODEL; DRUG EFFECT; HYPERTENSION; METABOLISM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; BENZOATES; BRAIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ELECTROSHOCK; HYPERTENSION; LOSARTAN; MALE; MICE; RECEPTOR, ANGIOTENSIN, TYPE 1; SEIZURES; VALPROIC ACID;

EID: 77953809403     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.053     Document Type: Article

References (47)

1. André V., Ferrandon A., Marescaux C., Nehlig A. The lesional and epileptogenic consequences of lithium-pilocarpine-induced status epilepticus are affected by previous exposure to isolated seizures: effects of amygdala kindling and maximal electroshocks. Neuroscience 2000, 99:469-481.
2. Bittigau P., Ikonomidou C. Glutamate in neurologic disease. J. Child. Neurol. 1997, 12:471-485.
3. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle methode simple pour explorer l'action 'tranquilisante': le test de la cheminee. Med. Exp. (Basel) 1960, 3:81-84.
4. Braszko J.J. Valsartan abolishes most of the memory-improving effects of intracerebroventricular angiotensin II in rats. Clin. Exp. Hypertens. 2005, 27:635-649.
5. Braszko J.J., Kułakowska A., Winnicka M.M. Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats. J. Physiol. Pharmacol. 2003, 54:271-281.
6. 1 receptor antagonism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:1231-1239.
7. Culman J., vonHeyer C., Piepenburg B., Rascher W., Unger T. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur. J. Pharmacol. 1999, 367:255-265.
8. Czuczwar S.J., Kleinrok Z. Modulation of the protective efficacy of common antiepileptic drugs by xanthine derivatives: implications for the clinical use of xanthines in epileptic patients. Pharmacol. Res. 1990, 22:661-665.
9. Czuczwar S.J., Patsalos P.N. The new generation of GABA enhancers. CNS Drugs 2001, 15:339-350.
10. Czuczwar S.J., Frey H.H., Löscher W. Antagonism of N-methyl-D, L-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur. J. Pharmacol. 1985, 108:273-280.
11. Czuczwar S.J., Swiader M., Kuźniar H., Gasior M., Kleinrok Z. LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur. J. Pharmacol. 1998, 359:103-109.
12. Dalby N.O., Thomsen C., Fink-Jensen A., Lundbeck J., Søkilde B., Man C.M., Sørensen P.O., Meldrum B. Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res. 1997, 28:51-61.
13. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
14. Ealls J.B., Clough R.W., Browning R.A., Jobe P.C. Comparative fos immunoreactivity in the brain after forebrain, brainstem, or combined seizures induced by electroshock, pentylenetetrazol, focally induced and audiogenic seizures in rats. Neuroscience 2004, 123:279-292.
15. Fujihara C.K., Velho M., Malheiros D.M., Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 2005, 67:1913-1924.
16. Gehlert D.R., Gackenheimer S.L., Schober D.A. Autoradiographic localization of subtypes of angiotensin II antagonist binding in the rat brain. Neuroscience 1991, 44:501-514.
17. Georgiev V.P., Lazarova M.B., Petkov V.D., Kambourova T.S. Interactions between angiotensin II. GABA and diazepam in convulsive seizures. Neuropeptides 1986, 7:329-336.
18. Georgiev V.P., Lazarova M.B., Kambourova T.S. Interactions between angiotensin II, diazepam, clonazepam and di-n-propylacetate in pentylenetetrazol kindling seizures in mice. Neuropeptides 1991, 18:187-191.
19. Georgiev V.P., Lazarova M.B., Kambourova T.S. Further evidence for the interactions between angiotensin II and GABAergic transmission in pentylenetetrazol kindling seizures in mice. Neuropeptides 1995, 28:29-34.
20. Georgiev V.P., Lazarova M.B., Kambourova T.S. Effects of non-peptide angiotensin II-receptor antagonists on pentylenetetrazol kindling in mice. Neuropeptides 1996, 30:401-404.
21. 1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J. Pharmacol. Exp. Ther. 2001, 298:62-70.
22. Jefferys J.G. Mechanisms and experimental models of seizure generation. Curr. Opin. Neurol. 1998, 11:123-127.
23. Jing G., Grammatopoulos T., Ferguson P., Schelman W., Weyhenmeyer J. Inhibitory effects of angiotensin on NMDA-induced cytotoxicity in primary neuronal cultures. Brain Res. Bull. 2004, 62:397-403.
24. Kułakowska A., Karwowska W., Wiśniewski K., Braszko J.J. Losartan influences behavioural effects of angiotensin II in rats. Pharmacol. Res. 1996, 34:109-115.
25. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96:99-113.
26. Löscher W. Basic pharmacology of valproate. CNS Drugs 2002, 10:669-694.
27. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8:79-94.
28. Luszczki J.J., Czuczwar S.J. How significant is the difference between drug doses influencing the threshold for electroconvulsions?. Pharmacol. Rep. 2005, 57:782-786.
29. Luszczki J.J., Borowicz K.K., Swiader M., Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44:489-499.
30. Myhrer T., Enger S., Aas P. Roles of perirhinal and posterior piriform cortices in control and generation of seizures: a microinfusion study in rats exposed to soman. Neurotoxicology 2010, 31:147-153.
31. Raghavendra V., Chopra K., Kulkarni S.K. Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides 1998, 32:417-421.
32. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
33. Ribeiro A.B. Angiotensin II antagonists-therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. Curr. Med. Res. Opin. 2006, 22:1-16.
34. A/benzodiazepine receptors: cellular and subcellular localization in the CNS with monoclonal antibodies. J. Neurosci. 1987, 7:1866-1886.
35. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 1990, 42:223-286.
36. Sills G.J., Brodie M.J. Update on the mechanisms of action of antiepileptic drugs. Epileptic Disord. 2001, 3:165-172.
37. Song K., Zhuo J., Mendelsohn F.A.O. Access of peripherally administered DuP 753 to rat brain angiotensin II receptors. Br. J. Pharmacol. 1991, 104:771-772.
38. Tchekalarova J., Georgiev V. Adenosine-angiotensin II interactions in pentylenetetrazol seizure threshold in mice. J. Physiol. (Paris) 1999, 93:191-197.
39. Tchekalarova J., Georgiev V. Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility?. Life Sci. 2005, 76:955-970.
40. Tchekalarova J., Kambourova T., Georgiev V. Angiotensin III and IV influence on pentylenetetrazol seizure susceptibility (threshold and kindling). Interaction with adenosine A1 receptors. Brain Res. Bull. 2001, 56:87-91.
41. Tracy H.A., Wayner M.J. Losartan blocks diazepam and ethanol effects on air righting. Alcohol 1998, 16:93-99.
42. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Carini D.J., Lee R.J., Wexler R.R., Saye J.A.M., Smith R.D. Angiotensin II receptor and angiotensin II receptor antagonists. Pharmacol. Rev. 1993, 45:205-251.
43. Venault P., Chapouthier G., Prado de Carvalho L., Simiand J., Morre M., Dodd R.H., Rossier J. Benzodiazepine impairs and β-carboline enhances performance in learning and memory tasks. Nature 1986, 321:864-866.
44. 1 receptor blockers. J. Cardiovasc. Pharmacol. 2003, 41:593-599.
45. Weinberg A.J., Zappe D.H., Ashton M., Weinberg M.S. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am. J. Nephrol. 2004, 24:340-345.
46. Wright J.W., Harding J.W. Important roles for angiotensin III and IV in the brain rennin-angiotensin system. Brain Res. Rev. 1997, 25:96-124.
47. Wright J.W., Yamamoto B.J., Harding J.W. Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog. Neurobiol. 2008, 84:157-181.